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Background: The progression of the nonalcoholic fatty liver
disease to nonalcoholic steatohepatitis (NASH) is multifac-
torial, and there is still a lack of approved medications for
its treatment. The study aimed to evaluate the impact of
combined treatment with Pentoxifylline and Metformin on
biochemical parameters in patients with NASH. Setting:
Outpatient hepatology clinic.
Methods: A prospective trial was conducted. The first
cohort included patients with biopsy-proven NASH, while
the second cohort consisted of patients with biopsy-con-
firmed NAFLD. Blood tests were checked at baseline and
every three months. Pentoxifylline at a dosage of 400 mg
t.i.d. and Metformin at the dosage of 500 mg t.i.d. were
introduced for six months in NASH group. The impact of
the treatment was assessed based on biochemical results
after combined treatment with low-cost medications. 
Results: All 33 NASH patients completed 24 weeks of
treatment. We observed significant improvement (p<0.05)
of median values after treatment for the following parame-
ters: serum uric acid levels decreased by 51.0 mmol/L, cal-
cium decreased for 0.27 mmoL/L, magnesium showed an
increase of 0.11 mmoL/L. Insulin resistance improved as a
Kratak sadr`aj
Uvod: Progresija nealkoholne masne bolesti jetre (NAFLD)
do nealkoholnog steatohepatitisa (NASH) je multifaktorijal-
na, i jo{ uvek ne postoje zvani~no odobreni lekovi za tera -
piju. U studiji je procenjivan uticaj kombinovane terapije
pentoksifilinom i metforminom na biohemijske parametre
kod pacijenata sa NASHom. Okru`enje: Hepatolo{ka am -
bu lanta klinike. 
Metode: Studija je bila prospektivnog karaktera. Prva grupa
uklju~ila je pacijente sa biopsijom potvr|enim NASHom,
dok su drugu grupu ~inili pacijenti sa biopsijom potvr |e -
nom NAFLDom. Analize krvi vr{ene su svaka tri meseca.
Uvedena je kombinovana terapija pentoksifilinom u dozi od
400 mg 3×1 i metforminom u dozi od 500 mg 3×1, u tra-
janju od {est meseci za NASH grupu. Efekat lečenja pro-
cenjen je na osnovu biohemijskih parametara nakon terapi-
je ovim medikamentima sa niskom cenom. 
Rezultati: Svih 33 pacijenta su zavr{ila 24 nedelje terapije.
Uo~eno je zna~ajno pobolj{anje (p<0,05) vrednosti medi-
jane za slede}e parametre: nivoi mokra}ne kiseline u se -
rumu su se snizili za 51,0 mmol/L, kalcijum je sni`en za
0,27 mmol/L, magnezijum je pokazao porast za 0,11
mmol/L. Pobolj{ana je insulinska rezistencija konstatovana
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Introduction 
The epidemic extent of nonalcoholic fatty liver
disease (NAFLD) reaching up to 30% of the general
population, has become the most common chronic
liver disease worldwide (1). Nonalcoholic steatohep-
atitis (NASH), a progressive form of NAFLD, was first
described almost 40 years ago, as a specific entity
characterized by fatty changes with lobular hepatitis in
patients with no history of alcoholism (2). It has
become increasingly identified since. Most studies are
reporting a prevalence of biopsy-proven NASH of 3 to
5 percent among NAFLD patients (3–5). This patient
population exhibits increased rates of liver-related
mortality as a result of cirrhosis and its complications,
including hepatocellular carcinoma (HCC) (6). The
aforementioned remark is corresponding to the
observation of NASH-associated cirrhosis becoming
the most common cause of liver transplantation,
exceeding hepatitis C virus and alcoholic related cir-
rhosis (7). Moreover, given the lack of understanding
of NAFLD prevalence added to NASH-associated cir-
rhosis, researchers note that the real disease burden
may be significantly higher (8).
The progression of NAFLD is multifactorial, and
there are currently no FDA-approved medications for
the treatment of NASH (9). One of the main obsta-
cles remains in a fact that the NASH triggers have not
been thoroughly recognized. Treatment options tar-
get different mechanisms responsible for the develop-
ment of the disease. At this point, the beneficial effect
to a certain extent has been shown by insulin-sensitiz-
ing agents, antioxidants, lipid-lowering agents,
angiotensin receptor blockers, and probiotics.
Promising results from the new drugs currently inves-
tigated in clinical trials, including obeticholic acid,
liraglutide, elafibranor, and aramchol are being evalu-
ated (10). Lifestyle modification focused on diet and
exercises continue to be the primary treatment
(11). The American Association for the Study of Liver
Diseases practice guideline suggests the loss of at
least 3–5% of body weight to improve steatosis, and
up to 10% to improve necroinflammation (12).
However, most patients who ask medical advice have
a long history of ineffective attempts at dietary and
lifestyle changes (13). Furthermore, many biochemi-
cal parameters, for instance, liver enzymes, platelets,
albumin, and scoring systems based on aforemen-
tioned markers, have been used to investigate NAFLD
(14–16).
Pentoxifylline (PTX), a phosphodiesterase inhi -
bitor, although commonly used for peripheral vascular
disease, is one of the antioxidants considered for
NASH treatment. Besides its antioxidant activity and
inhibition of proinflammatory cytokine production
(tumor necrosis factor alpha – TNF-a), it exerts
pleiotropic pharmacological effects (17). Additionally,
it has been implied that PTX reduces platelet-derived
growth factor and tumor growth factor beta-1mediat-
ed fibrosis (18, 19). A study by Zein et al. (20) noted
that PTX markedly reduced steatosis, lobular inflam-
mation, and liver fibrosis. Two meta-analyses revealed
a decrease in liver enzymes and histological benefit in
NASH patients after PTX therapy (21, 22). Metfor -
min (MET) exerts its effect on glucose homeostasis
via adenosine monophosphate-activated protein
kinase. It has proven certain benefits in NASH treat-
ment. Some studies detected a reduction in amino-
transferases levels in addition to the improvement of
insulin resistance (23, 24), though the lack of histo-
logical response (25).
Acknowledging the complexity of the disease, it
seems improbable that a single pharmacologic thera-
py will meet the requirements of the majority of this
specific patient population. Hence, our study aimed
to evaluate the efficacy of combination therapy of
PTX and MET by monitoring biochemical parameters
of patients with biopsy-diagnosed NASH. 
Materials and Methods
Data were collected prospectively from adult
patients who attended a routine examination at the
Clinic for Gastroenterology and Hepatology. Physical
examination, abdominal ultrasound, laboratory test-
ing, and liver biopsy were available for all patients.
The first cohort included patients with biopsy-proven
NASH. The second cohort consisted of age and gen-
der-matched pairs with biopsy-confirmed NAFLD.
Initially, all patients were instructed to follow the spe-
cific diet (British Liver Trust) and were counseled on
other lifestyle modifications.
reduction of HOMA – IR by 1.3 was detected. A significant
decrease of median in liver enzymes, alanine aminotrans-
ferase, aspartate aminotransferase and gamma-glutamyl-
transferase by 24.0 U/L, 9.1 U/L, 10.8 U/L respectively,
was noted. 
Conclusions: Pentoxifylline and Metformin may provide
possible treatment option in NASH. Some new potential
benefit of the therapy in improving liver function whilst
decreasing cardiovascular risk was perceived.
Keywords: NASH, pentoxifylline, metformin, treatment,
steatohepatitis
kroz smanjenje HOMA-IR za 1,3. Zabele`eno je zna~ajno
smanjenje medijane enzima jetre: alanin aminotransferaze
za 24,0 U/L, aspartat aminotransferaze za 9,1 U/L i gama
glutamiltransferaze za 10,8 U/L. 
Zaklju~ak: Pentoksifilin sa metforminom mo`e predstavljati
mogu}u terapijsku opciju u NASHu. Prime}ena je nova
potencijalna korist primenjene terapije u pobolj{anju
funkcije jetre i smanjenju kardiovaskularnog rizika. 
Klju~ne re~i: NASH, pentoksifilin, metformin, terapija,
steatohepatitis
292 Culafic et al.: Pentoxifylline with Metformin in NASH
Exclusion criteria were other forms of primary
hepatocellular liver diseases: hepatitis B, hepatitis C,
autoimmune hepatitis, Wilson disease, alpha-1-antit-
rypsin deficiency, hemochromatosis, drug-induced
liver disease. Patients on PTX or anti-diabetic drugs
(insulin, biguanides, sulfonylureas, or thiazolidine-
diones), amiodarone, methotrexate, tamoxifen, corti-
costeroids in the previous six months as well as
patients with a history of excess alcohol ingestion
(consumption of alcohol 20 g per day) were also
excluded from the study. Furthermore, this study dis-
missed patients with significant systemic or major ill-
nesses (congestive heart failure, coronary artery dis-
ease, cerebrovascular disease, a pulmonary disease
with hypoxia, renal failure, organ transplantation,
severe psychiatric disease, malignancy) that might
influence the treatment results. 
Abdominal ultrasonography
The abdominal ultrasound was performed using
a Toshiba core vision with Doppler duplex convex
probe 3.5 MHz. Corresponding to previous studies
following criteria were applied: the diffuse hyper-
echoic echotexture, hepatorenal echo contrast in ref-
erence to the cortex of the right kidney, vascular blur-
ring, and deep-echo attenuation (27, 28). 
Liver biopsy
Biopsies were performed for diagnostic purpos-
es, during regular follow-up. Menghini liver biopsy
needle was used. Histological criteria for steatohep-
atitis included: macrovesicular steatosis, hepatocellu-
lar injury, parenchymal and portal inflammation,
fibrosis stage. 
Laboratory measurements
All patients fasted overnight before physicians
saw them in the clinic. We determined their height
and weight, and body mass index (BMI) expressed as
a weight (kg) divided by the square of the height
(m2).
Blood samples were collected under standard
conditions between 7 and 8 am after 12h overnight
fast. K2-EDTA-anticoagulated blood was used for per-
forming complete blood count (Coulter LH 750,
Beckman Coulter, Inc., USA). The analysis of hema-
tological parameters were conducted immediately
upon sampling, serum was separated by centrifuga-
tion, and analysis were performed. Biochemical
parameters (glucose level, insulin, total cholesterol
(TC) and triglyceride concentrations (TG), high-den -
sity lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), high sensitivity C-
reactive protein (hs-CRP), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), gamma-
glutamyltransferase (GGT), serum uric acid levels
(SUA), calcium, magnesium, vitamin B12, folate and
homocysteine) were measured employing routine
methods (Olympus System reagents using Olympus
analyser AU 2700, Hamburg, Germany). Additionally,
insulin resistance was assessed by the homeostasis
model assessment (HOMA-IR) (26). Blood tests were
checked at baseline and every three months.
Drug treatment
PTX at a dosage of 400 mg t.i.d. and MET at
the dosage of 500 mg t.i.d. were introduced for six
months in NASH cohort.
Statistical analysis
Descriptive statistic was applied to provide basic
characteristics of the study population. The one-sam-
ple Kolmogorov-Smirnov test was performed to deter-
mine if the data showed normal distribution. Mann
Whitney test or T-test was used to compare parame-
ters between cohorts. Measured parameters were fur-
ther analyzed by Wilcoxon Signed Ranks Test in the
treatment group to detect potential differences in
data before and after medication use. A p value of
less than 0.05 was considered statistically significant.
The sample size was estimated based on Rosner cal-
culation (29). 
Ethical considerations
The study was conducted in accordance with
Guidelines for Good Clinical Practice, the Declaration
of Helsinki, and local laws and regulations. The pro-
tocol was approved by the joint Research and Ethics
Committee of the Clinical Centre of Serbia, Belgrade,
filed under number 262/2. Written informed consent
was obtained from all the participants in the study.
Results
Patients in the NASH cohort and NAFLD cohort
were similar in regards to their anthropometric and
ultrasonographic characteristics but showed differ-
ences in some biochemical parameters (Table I). We
included 33 patients with NASH and 30 NAFLD
patients. 
Adverse drug reactions
Patients reported the following adverse drug
reactions (ADRs) during the first month of treatment:
nausea (11%) and abdominal discomfort (14.9%). All
ADRs were transient and mild; thus all patients
included in the treatment group completed their 24
weeks medication regimen. 
Most NASH patients lost weight, 3.1± 1.6 kg
on average in observed six months period. 
Before and after drug treatment
We detected significantly different values after
three and six months when compared to the baseline
parameters before treatment in NASH cohort for the
following parameters: SUA, ALT, AST, GGT, calcium,
magnesium, and HOMA-IR, as presented in Table II.
In our study with given six months of NASH ther-
apy, median SUA levels decreased by 51.0 mmol/L;
serum calcium decreased by 0.27 mmoL/L, magne-
sium showed an increase of 0.11 mmol/L. We detect-
ed a decrease in median values of ALT, AST and GGT
by 24.0 U/L, 9.1 U/L, 10.8 U/L, respectively. Insulin
resistance improved as a reduction of HOMA – IR by
1.3 was observed. Other monitored parameters (vita-
min B12, homocysteine, folate) showed no statistical-
ly significant difference (p=0.106; 0.405; 0.203,
respectively).
When the comparison of parameters between
two cohorts, the NASH treatment group, and the
NAFLD group were applied after the study period, we
detected no significant difference for SUA, calcium,
AST, and GGT. 
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Age (years) 38.7 ± 8.1 40.8 ± 12.10 0.546
Male 20 20 /
Waist/Circumference 99.1 ± 11.9 103.1 ± 16.4 0.497
BMI (kg/m2) 27.3 ± 4.3 26.9 ± 3.5 0.844
Waist to hip ratio 0.9 ± 0.02 0.9 ± 0.02 0.965
WBC (109/L) 7.7 ± 2.3 8.7 ± 2.3 0.566
Hb (g/L) 136.0 ± 29.1 133.0 ± 21.2 0.307
MCH (pg) 28.8 ± 2.4 28.1 ± 2.0 0.778
MCHC (g/L) 35.8 ± 1.9 40.2 ± 2.9 0.452
RBC (1012/L) 4.9 ± 1.9 4.8 ± 0.9 0.664
PLT (109/L) 275.9 ± 55.9 288.9 ± 43.9 0.778
CLCr* (mL/min) 98.3 ± 21.8 101.27 ± 25.6 0.405
TC (mmoL/L) 5.9 ± 1.4 5.8 ± 1.4 0.011
HDL-C (mmoL/L) 1.1 ± 0.4 1.0 ± 0.5 0.602
LDL-C (mmoL/L) 3.1 ± 1.3 3.2 ± 1.2 0.839
TG (mmoL/L) 1.7 ± 1.0 1.8 ± 1.2 0.944
Calcium (mmoL/L) 2.2 ± 0.15 2.5 ± 0.09 0.054
Magnesium (mmoL/L) 0.85 ± 0.15 0.67 ± 0.09 0.050
ALT (U/L) 38.5 ± 13.7 70.2 ± 35.1 0.001
AST (U/L) 25.5 ± 14.3 39.4 ± 18.2 0.001
GGT (U/L) 47.2 ± 24.8 54.8 ± 34.3 0.214
CRP (mg/L) 3.1 ± 2.4 3.2 ± 2.8 0.713
SUA (mmol/L) 346.3 ± 84.7 398.01± 108.5 0.041
HbA1c 5.5 ± 1.9 5.6 ± 1.3 0.338
HOMA-IR 4.7 ± 0.9 5.2 ± 1.7 0.010
Data are given as mean ± standard deviation. BMI – body mass index, WBC – white blood cell count, Hgb – hemoglobin, MCH
– mean corpuscular hemoglobin, MCHC – mean corpuscular hemoglobin concentration, RBC – red blood cells, PLT -platelets
count; *CLCr – Creatinine Clearance calculated based on Cocroft-Gault formula; TC – total cholesterol, LDL – C - low-density
lipoprotein cholesterol, HDL-C – high-density lipoprotein cholesterol, TG – triglycerides, ALT – alanine aminotransferase, AST –
aspartate aminotransferase, GGT – gamma-glutamyl transferase, CRP – C-reactive protein, SUA – serum uric acid, HbA1C – gly-
cated haemoglobin, HOMA-IR – homeostasis model assessment of insulin resistance.
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However, magnesium, ALT, and HOMA-IR
showed significant difference among observed
cohorts after six months. In more details, ALT was
still elevated in NASH group compared to NAFLD
group (47.9 U/L vs. 37.7 U/L), magnesium
reached the reference range in NASH treatment
group but was lower than control group (0.77
mmoL/L vs. 0.90 mmoL/L), while HOMA-IR
showed a decrease by 1.1 in NASH cohort when
compared to NAFLD cohort (Figure 1).
Figure 1 Diagram showing comparison of parameters in NASH cohort -1 (n=33) vs NAFLD cohort -2 (n=30) (after six months);
SUA – serum uric acid, Ca – calcium, Mg – magnesium (1 vs 2, p<0.05), ALT – alanine aminotransferase (1 vs 2, p<0.05), AST
– aspartate aminotransferase, GGT – gamma-glutamyl transferase), HOMA-IR – homeostasis model assessment of insulin resist-
ance (1 vs 2, p<0.05).
Table II Comparison of biochemical parameters after three and six months of treatment with baseline NASH.
Data are given as median with interquartile range. SUA – serum uric acid, ALT – alanine aminotransferase, AST – aspartate amino-
transferase, GGT – gamma-glutamyl transferase, HOMA-IR – homeostasis model assessment of insulin resistance.
Parameters NASH before After 3 months p-value After 6 months p-value
SUA (mmoL/L) 391.2 (339.0–482.3) 366.0 (327.9–416.1) 0.050 340.2 (291.2–390.2) 0.002
Calcium (mmoL/L) 2.50 (2.43–2.60) 2.35 (2.15–2.45) 0.040 2.23 (2.11–2.39) 0.002
Magnesium (mmoL/L) 0.66 (0.63–0.71) 0.72 (0.67–0.76) 0.030 0.77 (0.73–0.79) 0.004
ALT (U/L) 71.0 (46.1–92.0) 57.8 (39.0–63.2) 0.050 47.0 (39–59.9) 0.001
AST (U/L) 36.4 (25.9–55.5) 29.3 (19.0–47) 0.002 27.1 (17–41) 0.002
GGT (U/L) 49.80 (26.6–75.3) 45.6 (25.2–65.9) 0.050 39.0 (26–56) 0.005
HOMA-IR 5.0 (4.1–6.1) 4.20 (3.2–5.0) 0.009 3.7 (2.9–4.8) 0.001
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Discussion
It is previously demonstrated that PTX and MET
have a positive effect when used as monotherapy in
NASH outcomes (21, 25). Thus, we aimed to explore
the combined effect of the drugs, comprehending the
multifactorial nature of NAFLD/NASH. Moreover,
biopsy-confirmed NAFLD cohort served as a control
group in our study, as all patients (NASH and NAFLD)
were instructed to follow the specific diet and were
counseled on other lifestyle modifications. NASH
group additionally received combined drug treat-
ment. To our knowledge, no studies of combination
MET-PTX treatment in NASH patients have been
published. Our data showed a substantial improve-
ment in specific biochemical parameters after com-
bined treatment in patients with biopsy-confirmed
NASH even after three months. Observed parameters
continued to improve after six months, with tolerable
and mild adverse drug events during treatment. The
NASH treatment group exhibited a similar profile in
most studied parameters when compared to NAFLD
control cohort after six months. Consequently, we
suggest longer treatment duration.
There is a growing body of evidence implying
that increased SUA has a role in NAFLD (30, 31).
Recently published studies have reported the associa-
tion of uric acid levels and metabolic syndrome and
NAFLD (32, 33) and furthermore recognized uric
acid (and dietary fructose intake) as an independent
factor associated with NASH (34). Hyperuricemia has
been linked to cardiovascular disease (35). When
NAFLD/NASH observed, the cardiovascular and not
hepatic disease has been identified as the most com-
mon cause of death among this population (36).
Moreover, hyperuricemia has been related to insulin
resistance, thus to hyperinsulinemia. This observation
has been further explained by fructose intake, which
may provoke metabolic syndrome and elevate uric
acid, whereas lowering uric acid averts manifestation
of metabolic syndrome (37). Our data identified high-
er levels of SUA in the NASH group when compared
to steatosis at a baseline, which confirms results from
cited studies.
Interestingly, a reduction of SUA levels was
detected after our drug intervention. This observation
may be explained by PTX effect on minimizing liver
damage while reducing SUA levels as suggested in
lately published research (38). Furthermore, PTX has
been indicated to restore depressed cardiac output
and improve hepatic perfusion and intestinal blood
flow in case of hemorrhage and resuscitation (39).
We hypothesized that MET also adds to this effect
through the reduction of insulin resistance, as we
observed significantly lower HOMA-IR after treat-
ment.
Notably, NASH patients had lower levels of
magnesium at baseline similar to data from newly
published research (40) but showed an increase in
serum magnesium after MET-PTX therapy. These
authors emphasized that lower serum magnesium
concentration was independently related to NASH.
Magnesium plays a role in insulin homeostasis, and
evidence showed an inverse correlation between
insulin resistance and magnesium intake, especially
in overweight individuals (41). Hence an explanation
may be related to insulin resistance observed in our
cohort as improving insulin resistance after given
treatment is expected to elevate magnesium levels.
This effect complies with MET mechanism of action.
Consequently, our findings on improving magnesium
levels with MET-PTX therapy add new insight into
their potential benefit.
Moreover, a Korean population study by Shin et
al. (42) revealed that elevated calcium and phospho-
rus levels were significantly related to NAFLD. Also, a
study by Park et al. (43) disclosed a positive correla-
tion between serum calcium and metabolic syndrome
(while the negative correlation between magnesium
and glucose). Our results go in line with these find-
ings, as the NASH group showed higher calcium lev-
els at a baseline. However, significantly lower calcium
levels were achieved after six months of PTX-MET
treatment. We argue that treatment added to reestab-
lishing the balance between ions, again through
improving insulin resistance.
As in previously published studies on patients on
MET therapy (23, 24, 44), our findings after NASH
treatment noted a significant decrease in liver amino-
transferases (ALT, AST, and GGT) after six months of
combination therapy. Furthermore, the HOMA-IR
score reduced after treatment. Besides a well-docu-
mented effect of MET, PTX may support this improve-
ment correspondingly to the results presented in a
study by Van Wagner et al. (45). 
Although in use for more than 50 years, MET
and PTX’s new beneficial properties are still being
discovered. PTX is a methylxanthine, like caffeine, for
which recent evidence indicates that increased caf-
feine intake may decrease liver fibrosis (46). In addi-
tion, if basic direct therapy costs were observed, MET
and PTX are low-cost medications. Having no
approved conventional therapy for the treatment of
NASH at this moment, health insurance not covering
the expenses of NASH treatment in our healthcare
system, hence patients are paying for the medicines
by themselves. Therefore, efficacy, safety, and price of
medicine should be considered when suggesting
treatment options for NASH in developing countries.
Despite the fact that this study is limited by the mod-
est number of patients, it sheds light on additional use
of easily available low-cost drugs, thus filling the
knowledge gap between rigid clinical trials and real-
life patient experience in actual clinical practice.
While the individual treatment of NASH includ-
ing patient-tailored lifestyle based on pharmacoge-
nomics expects to tackle the core of the disease (47),
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